Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction

Sponsored by Vahaticor

Anchorperson: B. Samuels

Spokesperson: T. Gori

Summary

This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach. The discussion also highlights the importance of coronary functional testing in identifying and characterising microvascular disease in routine clinical practice. Through case-based examples, the session illustrates diagnostic workflows, anatomical considerations of the coronary sinus, and early clinical outcomes, while outlining the next steps in clinical development.

Learning Objectives

To understand practical aspects of the implantation of a next generation self-expanding nitinol coronary sinus reducer
To learn about the clinical evidence from VahatiCor’s early feasibility SERRA I study for treating coronary microvascular dysfunction
To start assessing coronary microvascular function with coronary functional testing in your lab

Speaker

B. Samuels

Welcome and session objectives